1 / 62

Novel Therapeutics in Gynecological Malignancies

Novel Therapeutics in Gynecological Malignancies. Tamar Safra, MD Tel Aviv Sourasky Medical Center, Tel Aviv. Ovarian Cancer- New Treatments Uterine Cancer – Evolving Treatment. Ovarian Cancer. The most lethal of gynecologic malignancies Future goals Early detection

candide
Télécharger la présentation

Novel Therapeutics in Gynecological Malignancies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel Therapeutics in Gynecological Malignancies Tamar Safra, MD Tel Aviv Sourasky Medical Center, Tel Aviv

  2. Ovarian Cancer- New TreatmentsUterine Cancer – Evolving Treatment

  3. Ovarian Cancer • The most lethal of gynecologic malignancies • Future goals • Early detection • Development of novel agents

  4. Ovarian Cancer • New drugs and analogs of old drugs • New schedules for old drugs • Methods to overcome drug resistance • Biological agents • Combination of chemotherapy with biological therapy • Hormonal therapy

  5. Mitotic Spindle Inhibitors

  6. New Taxanes • Taxanes and epothilones - under active clinical development • Overcome drug resistance • Enhance tumor delivery • Reduced neuropathy • Reduced alopecia • Xyotax, a polyglutamate conjugated to paclitaxel - activity without alopecia • Abraxane - nanoparticle paclitaxel forumulation is under investigation

  7. Paclitaxel Poliglumex (PPX) • Conjugate of paclitaxel with poly-L-glutamic acid • Enhances distribution in tumor • Prolonged release of free paclitaxel • Greater activity • Active in tumors with MDR (Multi-Drug Resistance) gene • Shorter administration

  8. GOG 212 Phase III Study : Maintenance Chemotherapy for EOC Paclitaxel 175 mg/m2 q 28 days x 12 EOC with CR after 6 cycles of chemotherapy PPX 175mg/m2 q 28 days x 12 Observation

  9. Different Schedules of old drugs

  10. Topotecan • An S-phase specific drug • Activity and toxicity are schedule dependent • Investigated methods • Daily administration – 5 days q 3 weeks • Low‑dose continuous infusion (CI) • Weekly schedule

  11. Topotecan Mechanism of Action Topoisomerase I creates DNA breaks for repair and replication Topotecan binds to topoisomerase I creating DNA breaks Damage toDNA causescell death

  12. Topotecan Daily

  13. Study Design Multicenter, prospective, randomized phase-III study Topotecan 1.5 mg/m2/d D1-5 Q21d 30-minute infusion Stratification by age, ascites and previous response to platinum-based therapy Paclitaxel 175 mg/m2 D1 Q21d over 3 hours Ten Bokkel Huinink. J Clin Oncol 1997;15:2183-93

  14. 1.0 topotecan(n=112) 0.8 Paclitaxel (n=114) 0.6 P =.072 Proportion 0.4 0.2 0.0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 Time (weeks) Time to Progression Median TTP 19.8w 14.7w Ten Bokkel Huinink. Ann Onc. 2004;15:100-3

  15. Hematological Side Effects Ten Bokkel Huinink. J Clin Oncol 1997;15:2183-93

  16. Topotecan Continuous Infusion (CI)

  17. Continuous Infusion Phase-II 0.4 mg/m2/24h, D1-21 Q28d N=24 Response • RR - 35% (95% CI, 15% to 54%) • TTP - 26 weeks Grade III-IV toxicity • 31% neutropenia • 52% anemia requiring transfusion • 4% thrombocytopenia Hochster H. J Clin Oncol. 1999;17:2553-61

  18. Topotecan Weekly

  19. Weekly Topotecan in Patients with Recurrent or Persistent Epithelial Ovarian Cancer Phase-II Study Safra T, Inbar M, Levy T et al

  20. Objectives To investigate the safety and efficacy of weekly topotecan in relapsed and persistant EOC Safra T, Inbar M, Levy T et al

  21. Treatment Regimen 4 mg/m² topotecan D1,8,15 Q28d Safra T, Inbar M, Levy T et al

  22. Patients Characteristics • N=45 • Age – median 64y (range 42-87) • Stage – Ic-IIc in 4 (9%) patients III-IV in 41 (91%) patients • Platinum status – Sensitive 56% Resistant 44% • Previous chemotherapy – median 1(range 1-5) Safra T, Inbar M, Levy Taet al

  23. RESULTSResponse Rates Safra T, Inbar M, Levy T et al

  24. Time to Progression Median TTP 4.43m (95%CI, 3.64-5.23) Safra T, Inbar M, Levy T et al

  25. Overall Survival 1Y OS - 76% 2Y OS - 50% OS – median 11.6+ m (0.57-31) Safra T, Inbar M, Levy T et al

  26. Toxicity (2) Hochster H. J Clin Oncol. 1999;17:2553-61 (1) Ten Bokkel Huinink. Ann Onc. 2004;15:100-3

  27. Conclusions • Weekly topotecan is efficacious in relapsed and persistent EOC • Weekly topotecan is very feasible • Low rate of grade III-IV hematological toxicity • Mild non-hematological toxicity with no alopecia Safra T, Inbar M, Levy T et al

  28. Multiple Drug Resistance (MDR)

  29. Using Erlotinib To Overcome ABCG2-Mediated Chemoresistance To Topotecan Rebecca Kosloff, MD

  30. ABCG2 is one of the MDR genes Half-transporter structure causing efflux of the drug to the extracellular material Higher affinity for TKIs then other MDR1 Examples of TKI’s: Erlotinib Gefitinib Imatinib ABCG2

  31. Hypothesis Erlotinib to reverse ABCG2-mediated resistance to topotecan in ovarian cancer Topotecan Topotecan Intracellular extracellular ABCG2 Erlotinib

  32. Phase I and II and pharmacokinetics are on the way

  33. Biologics/targeted drug therapy

  34. Epidermal Growth Factor Receptor (EGFR)

  35. Extracellular Intracellular Transactivation P P Src PLCg GAP Grb2 Shc Nck Vav Grb7 Crk PKC Ras Abl JNK PI3KAkt MAPK Proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis Effects of HER1/EGFR Activation

  36. EGFR targeted therapy P P P TKIs Ligand– toxin conjugates Anti-ligand- blocking antibodies P Antibody– toxin conjugates Anti-HER1/EGFR-blocking antibodies 3 4 2 1 5 Noonberg SB, Benz CC. Drugs 2000;59:753–67

  37. Erbitux Herceptin Cell membrane Erlotinib Tyrosine-kinase domain HER1/EGFR HER2 Anti-HER monoclonal antibodies • Inhibit cell-cycle progression; potentiate apoptosis • Decrease production of angiogenic factors • Recruit natural killer cells to tumours • Enhance receptor internalisation Agus D, et al. Cancer Cell 2002;2:127–37Baselga J. Cancer Cell 2002;2:93–95

  38. Anti-EGFR studies have been initiated – most are not yet published • Anecdotal responses noted in phase I studies, encouraging phase II studies • Cetuximab (Erbitux) • Trastuzumab (Herceptin) - RR only 7.3%* • EMD72000 • GOG - a phase II study of cetuximab • EMD72000 - a phase II trial , completed but not yet reported • Combinations with chemotherapy are being studied in small scale * Bookman et al. J Clin Oncol. 21(2):283-90, 2003

  39. Small Molecules – TKI’s (Tyrosine Kinase Inhibitors)

  40. Erlotinib (Tarceva) • TKI –EGFR indicated in metastatic disease of pancreas and NSCLC • Inhibitor of ABCG2 • Preclinical data with topotecan • Some response as a single agent in ovarian cancer * • N=34 pts , heavily pretreated • RR 6% • SD 44% • Median OS 8 m • Erlotinib in combination with docetaxel and carboplatin as first line treatment for ovarian cancer shown some response ** * Gordon et al, Int J Gynecol Cancer 2005;15:785–792 **Finkler et al., ASCO Ann Meeting Proc 2001; 20:208a (abstr 831)

  41. Anti-angiogenic therapies

  42. The angiogenic switch in tumor development • Larger tumor • Vascular • Metastatic potential • Small tumor (1–2mm) • Avascular • Dormant Angiogenic switch Results in over-expressionof pro-angiogenic signals,such as VEGF Adapted from Bergers G, et al. Nature 2002;3:401–10

  43. Bevacizumab (Avastin) - a monoclonal antibody Prevents interaction VEGF with its receptors Prevents activation of downstream signalling pathways Vascular regression VEGF Bevacizumab X – P P– – P P– X Growth Proliferation Migration Survival Anti-VEGF antibody

  44. Blocking VEGF may cause existing tumour blood vessels to regress and lead to tumour shrinkage Shrinking tumour Regressing vasculature Jain RK. Nat Med 2001;7:987–9

  45. Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

  46. GOG 218: Bevacizumab Plus Standard Chemotherapy Randomization Placebo q 21 d x 15 mo Carboplatin plus Paclitaxel q 21 d x 6 Patients with previously untreated suboptimal advanced stage epithelial ovarian cancer or primary peritoneal cancer (N =2000) Placebo q 21 d x 15 mo Carboplatin plus Paclitaxel q 21 d x 6 plus Bevacizumab 15 mg/kg cycles 2-6 Bevacizumab q 21 d x 15 mo Carboplatin plus Paclitaxel q 21 d x 6 plus Bevacizumab 15 mg/kg cycles 2-6

  47. Endocrine Therapy

  48. Tamoxifen • Several positive phase II studies using tamoxifen • RR=17%* • 2 patients having greater than a 5 year response* • GOG-0198 - Phase III trial of tamoxifen compared with thalidomide in EOC * Ahlgren, et al. Journal of Clinical Oncology 1993, 11:1957-68.

  49. Aromatase inhibitors • A phase II study of Letrozole (Femara) 2.5 mg/d in 50 patients showed: • Ten patients with SD on CT for at least 12 weeks* • Response correlated with - higher estrogen receptors, lower erbB2, and higher EGFR* • Another phase II study ** of letrozole 2.5 mg/d with 27 patients showed: • RR of 15% • No correlation was found between response and estrogen/progesterone receptor expression • Aromatase inhibitors - need to be examined in Phase III studies and in combination with cytotoxic agents. * Bowman, et al. Clinical Cancer Research 2002, 8:2233-9. ** Papadimitriou, et al. Oncology 2004, 66(2):112-7.

  50. Locally Advanced Endometrial cancerChemotherapy Radiotherapy or Combination

More Related